Ignite Creation Date:
2024-10-25 @ 7:57 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06572722
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-23
Brief Title:
Perioperative Immunotherapy for NSCLC ECTOP-1030
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Perioperative Immunotherapy for Early-stage Non-small-cell Lung Cancer a Randomised Multicentre Open-label Phase 2 Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is a randomized multicenter open label phase II clinical study The main objective is to evaluate the efficacy of three perioperative immunotherapy modalities atezolizumab adjuvant therapy nivolumab neoadjuvant therapy pembrolizumab neoadjuvantadjuvant therapy in early-stage resectable NSCLC patients The enrolled patients are randomly assigned in a 111 ratio to receive relevant treatment in the three perioperative immunotherapy groups mentioned above and undergoing short-term pathological efficacy evaluation and long-term prognosis follow-up after surgery
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None